Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 190-196

  Claus, Rainer ^a,b   Pfeifer, Dietmar ^b   Almstedt, Maika ^b   Zucknick, Manuela ^a   Hackanson, Björn ^b   Plass, Christoph ^a   Lübbert, Michael ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

AML; Decitabine; DNA methylation; DNMT inhibition; Epigenetic therapy; Epigenetics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; MESSENGER RNA; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CD34 SELECTION; CDH1 GENE; CDKN2B GENE; CELL ISOLATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA METHYLATION; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; PRIORITY JOURNAL; TRANSCRIPTOMICS;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84872389658     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.015     Document Type: Article

References (32)

1. Claus R., Plass C., Armstrong S.A., Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol 2010, 6:1415-1431.
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
3. Bullinger L., Ehrich M., Döhner K., Schlenk R.F., Döhner H., Nelson M.R., et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115:636-642.
4. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
5. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
6. Lübbert M., Suciu S., Baila L., Rüter B.H., Platzbecker U., Giagounidis A., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29:1987-1996.
7. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
8. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
9. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., et al. Multicenter randomized open-label phase III trial of decitabine versus patient choice with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
10. Schmelz K., Sattler N., Wagner M., Lübbert M., Dörken B., Tamm I. Induction of gene expression by 5-aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005, 19:103-111.
11. Flotho C., Claus R., Batz C., Schneider M., Sandrock I., Ihde S., et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009, 23:1019-1028.
12. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5:e9001.
13. Qiu X., Hother C., Ralfkiaer U.M., Sogaard A., Lu Q., Workman C.T., et al. Equitoxic doses of 5-azacytidine and 5-aza-2'-deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS ONE 2010, 5:e12994.
14. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
15. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Mannari R.K., Gharybian V., et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66:5495-5503.
16. Oki Y., Jelinek J., Shen L., Kantarjian H.M., Issa J.P. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008, 111:2382-2384.
17. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
18. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7:2998-3005.
19. Pollyea D.A., Kohrt H.E., Gallegos L., Figueroa M.E., Abdel-Wahab O., Zhang B., et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2011, 26:893-901.
20. Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114:3448-3458.
21. Yan P., Frankhouser D., Murphy M., Tam H.H., Rodriguez B., Curfman J., et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012, (July). [published ahead of print].
22. Lübbert M., Rüter B.H., Claus R., Schmoor C., Schmid M., Germing U., et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97:393-401.
23. Duque-Afonso J., Solari L., Essig A., Berg T., Pahl H.L., Lübbert M. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. Br J Haematol 2011, 153:612-622.
24. Claus R., Hackanson B., Poetsch A.R., Zucknick M., Sonnet M., Blagitko-Dorfs N., et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 2012, 131:E138-E142.
25. Almstedt M., Blagitko-Dorfs N., Duque-Afonso J., Karbach J., Pfeifer D., Jäger E., et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010, 34:899-905.
26. Walter R.B., Othus M., Borthakur G., Ravandi F., Cortes J.E., Pierce S.A., et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011, 29:4417-4423.
27. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
28. Lapidot T., Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002, 16:1992-2003.
29. Kim H.K., De La Luz Sierra M., Williams C.K., Gulino A.V., Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006, 108:812-820.
30. Okada Y., Nagai R., Sato T., Matsuura E., Minami T., Morita I., et al. Homeodomain proteins MEIS1 and PBXs regulate the lineage-specific transcription of the platelet factor 4 gene. Blood 2003, 101:4748-4756.
31. Negrotto S., Ng K.P., Jankowska A.M., Bodo J., Gopalan B., Guinta K., et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2012, 26:244-254.
32. Jiemjit A., Fandy T.E., Carraway H., Bailey K.A., Baylin S., Herman J.G., et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008, 27:3615-3623.